Is Ixabepilone available in China?

Ixabepilone is an anti-microtubule chemotherapy drug for advanced or metastatic breast cancer , especially for patients who have previously failed to respond to paclitaxel, anthracyclines or other conventional chemotherapy regimens. By interfering with microtubule dynamic balance, ixabepilone prevents tumor cell division and induces apoptosis. Its unique mechanism of action also makes it effective in multidrug-resistant (MDR) breast cancer. Clinically, ixabepilone can not only be used as a single agent, but can also be combined with targeted drugs such as trastuzumab in specific regimens to enhance the anti-tumor effect. Its advantage is that it can provide more rescue treatment options for patients with advanced breast cancer, which is especially important in cases of recurrence or metastasis.

Currently, Ixabepilone has not been officially launched in China, so it cannot be purchased through formal channels in the domestic market and is not included in the medical insurance system. This means that if domestic patients need to use the drug, they can only obtain it through overseas channels and must follow strict international drug transportation and use regulations. In overseas markets, ixabepilone has been approved by the U.S. FDA and is available in different strengths, such as 15 mg and 45 mg, for intravenous infusion treatment. In terms of price, the 15mg specification is about US$2,000, and the 45mg specification is about US$6,000. There is currently no generic drug that can replace the original drug.

Because ixabepilone is a high-priced rescue drug, its use usually requires the guidance of professional oncologists, and an individualized plan is developed based on the patient's individual tolerance, tumor characteristics, and previous treatment history. Patients need to closely monitor hematological indicators, liver and kidney functions, and peripheral nerve reactions during use to ensure drug safety. In general, ixabepilone is an important rescue drug for advanced breast cancer. Although it has not yet been launched in China, its clinical value and international recognition provide new hope for patients with drug resistance or recurrence, and also promote the development direction of personalized anti-tumor treatment.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html